STAT3 and osteosarcoma: Telocinobufagin blocks STAT3 signaling in non-small-cell lung cancer and osteosarcoma [31,32], while bufotalin induces ferroptosis by GPX4 degradation, thus inhibiting non-small-cell lung cancer progression [33].